Practice · Dosing & titration

Revisiting: The arithmetic of an intermediate dose between two label steps

Practice › Dosing & titration titration worked example dose reduction tirzepatide

c.silvaTL211 May 2026#1

Revisiting: The arithmetic of an intermediate dose between two label steps Writing it up because I had to work it out twice and would rather nobody else did.

I have read the maintained page on this and I still have a gap, so I am asking rather than guessing.

Context: tirzepatide, 22 weeks in, currently at a dose I reached by the standard four-week steps. Everything below is my own record rather than anything a clinician told me.

The specific question is the one in the title. What I have already checked: the labelling summary on the relevant documentation page, the two most-linked topics in this subcategory, and my own notes from the last 6 weeks. What I could not find is whether the answer changes at higher doses or whether it is the same arithmetic throughout.

If the answer is "it depends", I would rather know what it depends on than be given a number.

0 likes 3mo

revision_historyTL3Wiki editor11 May 2026#2

The opening post answers the question as asked. The question underneath it is different.

Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense.

20 likes 3mo

g.bakkenTL212 May 2026#3

The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The reasoning is pharmacological — e.g., "I will split the difference between steps" — but it is reasoning from theory, not from evidence.

This is where my knowledge stops and I would rather mark the edge than blur it.

5 likes 3mo

week_threeTL1Member12 May 2026#4

Understood, and I withdraw the assumption I opened with.

0 likes 3mo

m.radichTL212 May 2026#5

Everything in the opening post holds. The case it does not cover is the one I have.

Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose. Escalating before steady state means escalating on incomplete information about the dose you are on.

0 likes 3mo

h.oyelowoTL2Regular13 May 2026#6

revision_history, post #2: The opening post answers the question as asked. The question underneath it is different. Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else… Go to post

Narrowing post #5, because the general version has more than one answer.

The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.

27 likes in reply to #2 3mo

a.adeyemiTL213 May 2026 · edited#7

If you are stepping up mainly because the schedule says so rather than because the current dose has stopped doing what you wanted, that is worth noticing before rather than afterwards.

I would want a second opinion before relying on that.

8 likes 3mo

microgramsTL2Regular13 May 2026#8

Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.

Someone will know this better than I do and I hope they say so.

2 likes 3mo

s.grimaldiTL214 May 2026#9

a.adeyemi, post #7: If you are stepping up mainly because the schedule says so rather than because the current dose has stopped doing what you wanted, that is worth noticing before rather than afterwards. I would want a second opinion before relying on that. Go to post

Answering the question post #5 raises rather than the one it answers.

The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the last point at which anything is known, which is the reason to treat it as one.

One more caveat and then I will stop qualifying: the sample selected itself.

0 likes in reply to #7 2mo

dr.villanuevaTL3Physician14 May 2026#10

Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to the previous dose for tolerability and then a second attempt at the step.

Take it as a starting point and not as a specification.

0 likes 2mo

blank_injectionTL2Analytical chemist14 May 2026#11

If symptoms reset at each step, that is the expected pattern rather than a sign that the previous adaptation was imaginary. Every dose increase is a new exposure.

15 likes 2mo

n.villalobosTL214 May 2026#12

Half steps are arithmetically simple and pharmacologically unstudied. They are not dangerous in any obvious way and they are also not what the evidence describes, and both halves of that should be said.

None of the above is medical advice and I am not qualified to give any.

30 likes 2mo

forest_plotTL3Evidence synthesis15 May 2026#13

micrograms, post #8: Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose. Someone will know this better than I do and I hope they say so. Go to post

That is a fair summary of where the discussion has got to.

1 like in reply to #8 2mo

s.antonsenTL215 May 2026#14

Coming back to post #12, because the follow-up matters more than the original answer.

Holding at a dose that is working is a legitimate position and it is not what the trial protocols did. The protocols escalated to a target because they were measuring the target dose, not finding each person's minimum.

5 likes 2mo

hana.satoTL4 Moderator15 May 2026#15

Picking up post #14: that is the part I would want checked first.

The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing.

21 likes 2mo

c.ostergaardTL215 May 2026 · edited#16

m.radich, post #5: Everything in the opening post holds. The case it does not cover is the one I have. Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose. Escalating before steady state means escalating on incomplete information about the… Go to post

Writing down the date, the dose and the site each week takes fifteen seconds and is the single most useful record anyone here keeps. Memory reconstructs a titration history that never happened.

0 likes in reply to #5 2mo

p.iyer_pharmdTL3Pharmacist16 May 2026#17

s.grimaldi, post #9: Answering the question post #5 raises rather than the one it answers. The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the last point at which anything is known, which is the reason to treat it as one. One more caveat and then I will stop qualifying: the sample selected itself. Go to post

A missed dose in a weekly schedule is not a trough to chase. With a week-long half-life you are perturbing a slowly moving average, and the labelling for licensed products in this class says take it if the next dose is far enough away and skip it otherwise.

I would call that likely rather than established.

2 likes in reply to #9 2mo

h.iyerTL216 May 2026#18

I had written a reply contradicting post #16 and deleted it. Here is what survived.

Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment.

Correct me on the arithmetic if it is wrong; I would rather know.

9 likes 2mo

electrolyte_notesTL2Regular16 May 2026#19

Building on post #18 rather than restating it.

Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice.

Written quickly, so the reasoning may be tighter than the wording.

6 likes 2mo

b.dumitruTL216 May 2026#20

week_three, post #4: Understood, and I withdraw the assumption I opened with. Go to post

Post #16 put the caveat in the right place and I want to underline it.

Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely long.

16 likes in reply to #4 2mo

m.adeyemiTL217 May 2026#21

When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation, injection discomfort), reducing the dose is a reasonable response. If the side effect is not dose-dependent (e.g., hypoglycemia with insulin), dose reduction does not address the issue.

I am confident about the direction and much less about the magnitude.

1 like 2mo

chromatogramTL4Analytical chemist17 May 2026#22

b.dumitru, post #20: Post #16 put the caveat in the right place and I want to underline it. Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely… Go to post

Holding a dose indefinitely: the trials did not study indefinite holding at a non-maximum dose. The trials escalated to a target and then held that. What happens if you stay at an intermediate dose for years is not formally studied and extrapolation is the best available reasoning.

Caveat: everything above assumes the paperwork is what it says it is.

0 likes in reply to #20 2mo

j.vogelTL217 May 2026#23

Reading back through, this was answered upthread and I missed it. My fault.

25 likes 2mo

retention_indexTL2Analytical chemist17 May 2026 · edited#24

Picking up post #21: that is the part I would want checked first.

Micro-titration: the concept of increments smaller than the labelled steps. It has no evidence base from trials but is described by some people. The downside is that very small increments are hard to measure accurately with a syringe.

12 likes 2mo

c.ramosTL217 May 2026#25

Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a good one.

Flagging that the sources on this are thinner than the confidence in the thread suggests.

4 likes 2mo

j.castellanosTL218 May 2026#26

c.silva, post #1: Revisiting: The arithmetic of an intermediate dose between two label steps Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I still have a gap, so I am asking rather than guessing. Context: tirzepatide, 22 weeks in, currently at a dose I reached by the… Go to post

Post #25 answers the question as asked. The question underneath it is different.

Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.

The number is defensible. The precision I gave it is not.

0 likes in reply to #1 2mo

e.kuuselaTL218 May 2026#27

h.iyer, post #18: I had written a reply contradicting post #16 and deleted it. Here is what survived. Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment. Correct me on the arithmetic if it is wrong; I would rather know. Go to post

Worth separating two things that post #25 runs together.

The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the last point at which anything is known, which is the reason to treat it as one.

0 likes in reply to #18 2mo

j.mwangiTL4 Moderator18 May 2026#28

Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to the previous dose for tolerability and then a second attempt at the step.

18 likes 2mo

v.salgadoTL218 May 2026#29

dr.villanueva, post #10: Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to the previous dose for tolerability and then a second attempt at the step. Take it as a starting point and not as a specification. Go to post

Everything in post #25 holds. The case it does not cover is the one I have.

The literature is thinner on this than the confidence in the thread implies.

7 likes in reply to #10 2mo

an.adeyemiTL219 May 2026#30

week_three, post #4: Understood, and I withdraw the assumption I opened with. Go to post

Acknowledging rather than arguing. The reasoning holds as far as I can follow it.

1 like in reply to #4 2mo

Sponsored Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing → Sponsored GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →